@Article{Kuroda2021,
journal="Polish Journal of Pathology",
issn="1233-9687",
volume="72",
number="3",
year="2021",
title="Review of TFEB-amplified renal cell carcinoma with focus on clinical and pathobiological aspects",
abstract="The disease entity of TFEB-amplified renal cell carcinoma (RCC) has been recently established. In this article, we review such cases. Clinically, the age of patients ranged from 28 to 83 years with a mean age of 62.8 years. The size of the tumor ranged from 1.9 to 19.5 cm with a mean size of 8.7 cm. The tumor demonstrated a variety of architectural patterns such as solid, alveolar, papillary, pseudopapillary, nested or tubular. The International Society of Urological Pathology (ISUP) grade usually corresponds to grade 3 or 4. Cytomorphology shows eosinophilic, clear, amphophilic or even oncocytic cytoplasm. Necrosis can be frequently observed. Neoplastic cells with TFEB-amplified RCC show diffuse or patchy positivity for TFEB. Fluorescence in situ hybridization frequently show the amplification of more than 10 or 20 copies of the TFEB gene. Most TFEB-amplified RCCs behave in an aggressive fashion. Metastasis frequently occurs. In conclusion, this tumor seems to be characterized by occurrence in older patients, frequent necrosis, papillary/pseudopapillary growth pattern, high-grade nuclear grade, TFEB gene amplification, and aggressive clinical behavior. In order to clarify whether this tumor is a distinct entity from previously described renal tumors or not, a further examination in a large scale study will be required in the future.",
author="Kuroda, Naoto
and Sugawara, Emiko
and Ohe, Chisato
and Kojima, Fumiyoshi
and Ohashi, Riuko
and Mikami, Shuji
and Nagashima, Yoji
and Peckova, Kvetoslava
and Michal, Michal
and Hes, Ondrej",
pages="197--199",
doi="10.5114/pjp.2021.111769",
url="http://dx.doi.org/10.5114/pjp.2021.111769"
}